Arca
Skip to content

Mantle cell lymphoma

Drug research and approvals for mantle cell lymphoma: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 16, 2026, 118 studies of mantle cell lymphoma are recruiting on ClinicalTrials.gov, Health Canada has authorized 13 drug trials for it since 2013, FDA has 12 approved and 16 open orphan designations naming it, and the EU has 2 authorised medicines for it.

  • Recruiting worldwide: 118
  • Trials authorized in Canada: 13
  • FDA orphan approvals: 12
  • EU medicines: 2

Recruiting Now

Newest start dates first, of 118 recruiting on ClinicalTrials.gov ↗

Trials Authorized in Canada

The 10 newest of 13; search them all in Canada trials
Dec 22, 2025A phase II study of sonrotoclax plus zanubrutinib in patients with relapsed/refractory mantle cell lymphoma planned for standard of care car-t cell therapySONROTOCLAX / ZANUBRUTINIBCANADIAN CANCER TRIALS GROUP, CANCER RESEARCH INSTITUTE, QUEEN'S UNIVERSITYOngoing
Jul 28, 2023A multicentre, phase II, open-label study to evaluate the efficacy of acalabrutinib in combination with venetoclax and rituximab in participants with treatment…ACALABRUTINIB/ VENETOCLAX/ RITUXIMABAstraZeneca Pharmaceuticals LPOngoing
Jul 6, 2023A phase III, open-label, multicenter, randomized study evaluating glofitamab as a single agent versus investigator¿s choice in patients with…COLUMVI / GAZYVA / RITUXAN / BENDAMUSTINE / LENALIDOMIDERocheOngoing
May 31, 2023A phase 1, open-label, multicenter, dose escalation study of prt1419 injection as monotherapy or in combination with azacitidine or venetoclax in patients with…PRT1419 / VENETOCLAX / AZACITIDINEPRELUDE THERAPEUTICSClosed
Dec 15, 2022A single-arm, open-label, multicenter phase 1/2 study to evaluate the efficacy, safety, and pharmacokinetics of bcl-2 inhibitor bgb-11417 in patients with…SONROTOCLAX (BGB-11417)BeOne MedicinesClosed
Oct 26, 2021A phase 3 randomized, open-label, multicenter study comparing zanubrutinib (bgb-3111) plus rituximab versus bendamustine plus rituximab in patients with…ZANUBRUTINIB (BGB-3111) / RITUXIMAB/ BENDAMUSTINEBeOne MedicinesOngoing
Mar 19, 2021A phase 3 open-label, randomized study of loxo-305 versus investigator choice of btk inhibitor in patients with previously treated btk inhibitor naïve mantle…PIRTOBRUTINIB (LOXO-305)Eli LillyOngoing
Jul 24, 2020A phase II study of acalabrutinib in combination with r-chop chemotherapy in previously untreated mantle cell lymphomaACALABRUTINIBUNIVERSITY HEALTH NETWORKOngoing
May 2, 2018A phase 1, first-in-human, open-label study evaluating the safety, tolerability, pharmacokinetics, and efficacy of amg 562 in subjects with relapsed /…AMG 562AmgenClosed
Jun 22, 2017Phase 3 study of ibrutinib in combination with venetoclax in subjects with mantle cell lymphomaIBRUTINIB/ VENETOCLAX/ FLUDEOXYGLUCOSE 18FAbbVieClosed

FDA Orphan Designations

Approved first, then open designations, newest first; 15 of 28
May 13, 2026Beqalzitreatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including…BeOne Medicines USA, Inc.Approved
Jan 16, 2025Calquencein combination with bendamustine and rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who…Acerta Pharma, LLC (a member of the AstraZeneca Group)Approved
May 30, 2024Breyanzitreatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have received at least 2 prior lines of systemic…Juno Therapeutics, Inc.Approved
Jan 27, 2023Jaypircatreatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including…Loxo Oncology, Inc.Approved
Aug 4, 2022CalquenceTreatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapyAcerta Pharma, LLC (a member of the AstraZeneca Group)Approved
Jul 24, 2020TECARTUS™TECARTUS¿ is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL)Kite Pharma, Inc.Approved
Nov 14, 2019BRUKINSABRUKINSA is indicated for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.BeOne Medicines USA, Inc.Approved
Oct 31, 2017CALQUENCEtreatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapyAcerta Pharma, LLC (a member of the AstraZeneca Group)Approved
Oct 8, 2014VelcadeTreatment of patients with mantle cell lymphoma.Takeda Pharmaceuticals U.S.A., Inc.Approved
Nov 13, 2013ImbruvicaTreatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapyPharmacyclics, LLCApproved
Jun 5, 2013RevlimidTreatment of mantle cell lymphoma whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib.Celgene CorporationApproved
Dec 8, 2006VelcadeTreatment of patients with mantle cell lymphoma who have received at least 1 prior therapy.Takeda Pharmaceuticals U.S.A., Inc.Approved
Feb 25, 2025an antibody-drug conjugate composed of the humanized…treatment of mantle cell lymphomaHangzhou Zhongmei Huadong Pharmaceutical Co., LtdDesignated
Feb 20, 2024CAR-T cell engager protein that links the CD19-directed…Treatment of mantle cell lymphomaAleta BiotherapeuticsDesignated
Dec 5, 2023tacabrutidegTreatment of Mantle Cell LymphomaBeOne Medicines USA, Inc.Designated

Medicines Authorised in the EU

Newest first
Oct 30, 2023JaypircapirtobrutinibEli Lilly Nederland B.V.EMA ↗
Dec 14, 2020Tecartusbrexucabtagene autoleucel · orphanKite Pharma EU B.V.EMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.